Lupin gets USFDA nod for insomnia drug

The company has received final approval for its Zolpidem Tartrate Extended-release tablets

major today said it has received US health regulator's approval to market a generic version of Sanofi Aventis' Ambien CR Extended-release tablets, used in treating sleep disorders, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) for its Zolpidem Tartrate Extended-release tablets in strengths of 6.25 mg and 12.5 mg, Lupin Ltd said in a statement.

"Lupin's wholly-owned US subsidiary Lupin Pharmaceuticals Inc shall commence marketing the product shortly," it added.

The product of the Mumbai-based company is indicated for the treatment of characterised by difficulties with sleep onset or sleep maintenance.

As per the IMS MAT March 2013 sales data, Sanofi's Ambien CR Extended-release tablets had annual US sales of nearly USD 366 million.

Lupin's cumulative abbreviated new drug application (ANDA) filings with the stands at 177 with the company having received 86 approvals as of the quarter ended June 30, 2013.

Shares of Lupin today closed down by 2.67% at Rs 838.40 on the BSE.

image
Business Standard
177 22
Business Standard

Lupin gets USFDA nod for insomnia drug

The company has received final approval for its Zolpidem Tartrate Extended-release tablets

Press Trust of India  |  New Delhi 



major today said it has received US health regulator's approval to market a generic version of Sanofi Aventis' Ambien CR Extended-release tablets, used in treating sleep disorders, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) for its Zolpidem Tartrate Extended-release tablets in strengths of 6.25 mg and 12.5 mg, Lupin Ltd said in a statement.



"Lupin's wholly-owned US subsidiary Lupin Pharmaceuticals Inc shall commence marketing the product shortly," it added.

The product of the Mumbai-based company is indicated for the treatment of characterised by difficulties with sleep onset or sleep maintenance.

As per the IMS MAT March 2013 sales data, Sanofi's Ambien CR Extended-release tablets had annual US sales of nearly USD 366 million.

Lupin's cumulative abbreviated new drug application (ANDA) filings with the stands at 177 with the company having received 86 approvals as of the quarter ended June 30, 2013.

Shares of Lupin today closed down by 2.67% at Rs 838.40 on the BSE.

RECOMMENDED FOR YOU

Lupin gets USFDA nod for insomnia drug

The company has received final approval for its Zolpidem Tartrate Extended-release tablets

The company has received final approval for its Zolpidem Tartrate Extended-release tablets major today said it has received US health regulator's approval to market a generic version of Sanofi Aventis' Ambien CR Extended-release tablets, used in treating sleep disorders, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) for its Zolpidem Tartrate Extended-release tablets in strengths of 6.25 mg and 12.5 mg, Lupin Ltd said in a statement.

"Lupin's wholly-owned US subsidiary Lupin Pharmaceuticals Inc shall commence marketing the product shortly," it added.

The product of the Mumbai-based company is indicated for the treatment of characterised by difficulties with sleep onset or sleep maintenance.

As per the IMS MAT March 2013 sales data, Sanofi's Ambien CR Extended-release tablets had annual US sales of nearly USD 366 million.

Lupin's cumulative abbreviated new drug application (ANDA) filings with the stands at 177 with the company having received 86 approvals as of the quarter ended June 30, 2013.

Shares of Lupin today closed down by 2.67% at Rs 838.40 on the BSE.
image
Business Standard
177 22
Widgets Magazine

More News

  • Future imperfect for Indian startups Philippines aims to breath life into start-up ecosystem
  • India to be amongst top five global pharma innovation hubs by 2020: Assocham India to be amongst top five global pharma innovation hubs by 2020: Assocham
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard